What Happened?
Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings topping analysts' expectations. Sales rose 10.5% year-on-year, fueled by high demand for its radiopharmaceutical products, including PYLARIFY, which crossed $1 billion in annual sales. For 2025, the company set a bullish earnings forecast, well above consensus estimates. However, its full-year revenue outlook came in slightly below expectations, pointing to a more cautious growth path. Overall, the quarter was decent, showcasing areas of strength in key product lines while highlighting some challenges, particularly in balancing revenue growth with increased spending on future initiatives.
Is now the time to buy Lantheus? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Lantheus’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. But moves this big are rare even for Lantheus and indicate this news significantly impacted the market’s perception of the business.
Lantheus is up 6.5% since the beginning of the year, but at $94.60 per share, it is still trading 23.5% below its 52-week high of $123.62 from July 2024. Investors who bought $1,000 worth of Lantheus’s shares 5 years ago would now be looking at an investment worth $5,804.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
